US 11,884,717 B2
Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
Vijay K. Kuchroo, Boston, MA (US); Chao Wang, Boston, MA (US); Aviv Regev, Cambridge, MA (US); and Karthik Shekhar, Cambridge, MA (US)
Assigned to The Brigham and Women's Hospital, Inc., Boston, MA (US); The Broad Institute, Inc., Cambridge, MA (US); and Massachusetts Institute of Technology, Cambridge, MA (US)
Filed by The Brigham and Women's Hospital, Inc., Boston, MA (US); The Broad Institute, Inc., Cambridge, MA (US); and Massachusetts Institute of Technology, Cambridge, MA (US)
Filed on Apr. 9, 2021, as Appl. No. 17/226,506.
Application 17/226,506 is a continuation of application No. 15/777,054, granted, now 11,001,622, previously published as PCT/US2016/062592, filed on Nov. 17, 2016.
Claims priority of provisional application 62/257,589, filed on Nov. 19, 2015.
Prior Publication US 2021/0317186 A1, Oct. 14, 2021
Int. Cl. A61K 38/20 (2006.01); A61K 38/17 (2006.01); C07K 14/705 (2006.01); A61P 37/00 (2006.01); A61P 1/00 (2006.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 14/54 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C12N 15/113 (2010.01); A61K 39/00 (2006.01)
CPC C07K 14/70596 (2013.01) [A61K 38/177 (2013.01); A61K 38/1709 (2013.01); A61K 38/208 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01); A61P 35/00 (2018.01); A61P 37/00 (2018.01); C07K 14/5434 (2013.01); C07K 16/244 (2013.01); C07K 16/2896 (2013.01); C12N 15/1136 (2013.01); C12N 15/1138 (2013.01); A61K 2039/575 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/20 (2017.05)] 2 Claims
 
1. A method of suppressing an immune response in a subject, the method comprising administering to the subject a therapeutically effective amount of
a recombinant soluble CD5L:p40 heterodimer, wherein the subject has an autoimmune disease.